Division of Infectious Diseases, Department of Internal Medicine, Bucheon St. Mary's Hospital, Bucheon, Korea.
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Korean Med Sci. 2021 Feb 8;36(6):e54. doi: 10.3346/jkms.2021.36.e54.
Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and has spread worldwide, has remained unabated in 2021. Since non-pharmaceutical interventions including social distancing are facing limitations in controlling COVID-19, additional absolute means to change the trend are necessary. To this end, coronavirus-specific antiviral drugs and vaccines are urgently needed, but for now, the priority is to promote herd immunity through extensive nationwide vaccination campaign. In addition to the vaccines based on the conventional technology such inactivated or killed virus or protein subunit vaccines, several vaccines on the new technological platforms, for example, nucleic acids-based vaccines delivered by viral carriers, nanoparticles, or plasmids as a medium were introduced in this pandemic. In addition to achieving sufficient herd immunity with vaccination, the development of antiviral treatments that work specifically against COVID-19 will also be necessary to terminate the epidemic completely.
2019 年底开始并在全球范围内传播的 2019 冠状病毒病(COVID-19)在 2021 年仍未得到控制。由于包括社交距离在内的非药物干预措施在控制 COVID-19 方面面临限制,因此需要采取其他绝对措施来改变这种趋势。为此,急需针对冠状病毒的抗病毒药物和疫苗,但目前的当务之急是通过广泛的全国性疫苗接种运动来促进群体免疫。除了基于传统技术(例如灭活或杀死的病毒或蛋白亚单位疫苗)的疫苗外,在此次大流行中还引入了几种基于新技术平台的疫苗,例如,病毒载体、纳米颗粒或质粒作为载体的核酸疫苗。除了通过接种疫苗实现足够的群体免疫外,还需要开发专门针对 COVID-19 的抗病毒治疗方法,以彻底终止疫情。